IAC (NASDAQ:IAC) Azioni

IAC INC

IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.

Chinese,Internet,Company,Sohu,Logo,Is,Seen,On,An,Android

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

SOHU

Opportunità nel settore tecnologico? L&#39;analisi evidenzia titoli sottovalutati pronti per una possibile inversione di tendenza.

3 azioni che si stanno preparando a crescere nel secondo trimestre

FUBO

GETY

Un&#39;analisi dei titoli di mercato che mostrano segnali di crescita imminente, che rappresentano un&#39;opportunità interessante per investire.

Queste 3 azioni tecnologiche potrebbero esplodere questo trimestre

IAC Inc

IAC/InterActiveCorp (New) COM WHENISSUED

INTER ACTION CP YOKOHAMA by Inter Action Corp. Yokohama

Inter Action Corp

Offerings

Dorian LPG Files For Potential Mixed Shelf; Size Not Disclosed

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 9.69% on an annualized basis producing an average annual return of 21.89%. Currently, Regeneron Pharmaceuticals has a market capitalization of $52.77 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $1,840.98 today based on a price of $488.79 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748987111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Rumors

$BTC

Watching Trump Media & Technology Group; Traders Circulate President Trump's Truth Social Files For A Bitcoin ETF

<a href="https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

BNTX

MRNA

NVAX

US Health Secretary Kennedy Posts On X "I want to address those of you who have anxieties about @US_FDA's limited approval of a new mRNA COVID vaccine for high-risk populations. Moderna has agreed to a true placebo-controlled trial of the new vaccine....."

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 2.2% on an annualized basis producing an average annual return of 15.22%. Currently, Devon Energy has a market capitalization of $20.54 billion. 
Buying $1000 In DVN: If an investor had bought $1000 of DVN stock 5 years ago, it would be worth $2,192.47 today based on a price of $31.92 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748986211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Devon Energy Stock In The Last 5 Years

Recently disclosed clinical cohort data from high (1x1015&nbsp;total vg) and low dose (5.7x1014&nbsp;total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102
Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vectors in non-human primates
Symposium on Rett syndrome natural history data findings
DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place in&nbsp;Boston from&nbsp;June 9-11, 2025. The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF's <a href="https://www.globenewswire.com/Tracker?data=fRcesPdJZ6naTCRmA1KdBnqknjMPiqUOSAZbibyIduSLIZBHD1sKDusevNNC9IDpOhcz49wKMcjwGxoZlu3UJQq_yJHoYjp2wi2ObKNmW3dZm0YC9_b3FmpZWcqr8vQ-RiqQI0N_8TElkfU9BZ2OAajR6CbuQwJ7QUjVqGCV5og=">website</a>.

Biotech

TSHA

Taysha Gene Therapies To Present Clinical And Preclinical Data Supporting TSHA-102 Rett Syndrome Program, Including Dose Cohort Results, Caregiver Insights Aligning With FDA Endpoints, At IRSF Scientific Meeting June 9–11, 2025 In Boston

LUCD

Lucid Diagnostics Files For Offering Of 36M Shares Of Common Stock

Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares are rising in extended trading on Tuesday after the company updated its guidance for the current quarter ahead of a <a href="https://www.benzinga.com/topic/bofa">scheduled presentation this week</a>.
What Happened: After the market close on Tuesday, Lumentum said it now expects fourth-quarter revenue of $465 million to $475 million, up from prior guidance of $440 million to $470 million.
The company noted that it expects to achieve $500 million of revenue in the first quarter of fiscal 2026, a quarter earlier than previously planned. 
Lumentum also raised its fourth-quarter earnings guidance from a range of 70 cents to 80 cents per share to a new range of 78 cents to 85 cents per share. The company said it anticipates a fourth-quarter operating margin of 14% to 15%, up from prior guidance of 13% to 14%.
Lumentum&#8217;s management team will discuss the updated forecast at the BofA Securities 2025 Global Technology Conference&nbsp;on Wednesday. 
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45759307/sportsmans-warehouse-stock-tanks-after-q1-earnings-revenues-miss-details">Sportsman&#8217;s Warehouse Stock Tanks After Q1 Earnings, Revenues Miss: Details</a>
<h1 class="wp-block-heading">How To Buy LITE Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For Lumentum, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
LITE Price Action: Lumentum shares were up 3.67% in after-hours, trading at $80.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

LITE

Lumentum Stock Jumps After The Close On Rosier Outlook

Unitil Corp Files For Stock Shelf; Size Not Disclosed

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 37.8% on an annualized basis producing an average annual return of 50.82%. Currently, Axon Enterprise has a market capitalization of $59.09 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $818.05 today based on a price of $759.07 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748985312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXON

$100 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 7.59 percent decrease over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $1.10 billion which missed the analyst consensus estimate of $1.11 billion by 0.59 percent. This is a 19.80 percent increase over sales of $921.04 million the same period last year.

Earnings Beats

Earnings Misses

CRWD

CORRECTION: CrowdStrike Holdings Q1 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $1.10B Miss $1.11B Estimate

WIIM

SPWH

SPWH stock has given up its prior loss. Sportsman's Warehouse shares were trading lower after the company reported worse-than-expected Q1 financial results.

Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.33 by 15.15 percent. This is a 9.52 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $7.63 billion which beat the analyst consensus estimate of $7.50 billion by 1.69 percent. This is a 5.87 percent increase over sales of $7.20 billion the same period last year.

CORRECTION: Hewlett Packard Q2 Adj. EPS $0.38 Beats $0.33 Estimate, Sales $7.63B Beat $7.50B Estimate

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Health Care

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.52 million which beat the analyst consensus estimate of $55.59 million by 1.68 percent. This is a 10.12 percent increase over sales of $51.33 million the same period last year.

BASE

CORRECTION: Couchbase Q1 Adj. EPS $(0.06) Beats $(0.08) Estimate, Sales $56.52M Beat $55.59M Estimate

EPR Properties: Files For Mixed Shelf Offering; Size Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares increased by 33.7% to $2.3 during Tuesday's after-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) shares rose 26.14% to $2.99. The market value of their outstanding shares is at $4.5 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock moved upwards by 17.68% to $0.2. The market value of their outstanding shares is at $2.8 million. </li>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares moved upwards by 14.74% to $37.75. The company's market cap stands at $577.5 million. </li>
<li>NFT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MI#AMEX">MI</a>) stock rose 10.08% to $2.62. The market value of their outstanding shares is at $13.2 million. </li>
<li>ZW Data Action Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) shares moved upwards by 7.51% to $1.43. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GD Culture Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) stock decreased by 6.0% to $2.65 during Tuesday's after-market session. The market value of their outstanding shares is at $44.5 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) stock decreased by 5.34% to $0.75. The company's market cap stands at $10.7 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares declined by 4.77% to $1.0. The company's market cap stands at $17.2 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) stock declined by 4.74% to $0.56. The market value of their outstanding shares is at $6.0 million. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock decreased by 3.9% to $1.48. The company's market cap stands at $83.2 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares decreased by 3.82% to $1.25. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTE

BAOS

BHAT

BLMZ

CNET

MCTR

NIPG

QMMM

12 Communication Services Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) stock increased by 29.5% to $5.18 during Tuesday's after-market session. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.05% to $5.78. The company's market cap stands at $154.4 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares moved upwards by 6.86% to $0.45. The market value of their outstanding shares is at $19.8 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares rose 6.8% to $0.79. The company's market cap stands at $61.0 million. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) stock moved upwards by 6.48% to $5.68. The company's market cap stands at $268.2 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 6.44% to $0.38. The company's market cap stands at $12.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 15.2% to $0.05 during Tuesday's after-market session. The company's, Q1 earnings came out yesterday. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 12.3% to $5.92. The company's market cap stands at $4.3 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 11.35% to $2.5. The company's market cap stands at $6.4 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares fell 8.27% to $25.3. The market value of their outstanding shares is at $33.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 8.21% to $0.35. The market value of their outstanding shares is at $2.0 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 7.63% to $0.73. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

CLSD

CYCCP

GTBP

HBIO

LIMN

LYRA

NCNA

PSTV

RSLS

WINT

12 Health Care Stocks Moving In Tuesday's After-Market Session

YIBO

Planet Image International Files For Mixed Shelf Of Up To $100M

<h3>Gainers</h3>
<ul>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares increased by 12.5% to $3.5 during Tuesday's after-market session. The company's market cap stands at $14.7 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 10.81% to $0.51. The market value of their outstanding shares is at $73.0 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares rose 6.32% to $1.68. The company's market cap stands at $18.4 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) shares rose 5.99% to $0.67. The market value of their outstanding shares is at $35.1 million. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) shares rose 5.73% to $2.58. The company's market cap stands at $56.7 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) stock rose 5.7% to $2.78. The company's market cap stands at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock declined by 7.5% to $0.27 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Conduent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) stock decreased by 6.12% to $2.3. The company's market cap stands at $372.2 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock declined by 5.25% to $1.08. The company's market cap stands at $59.9 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares decreased by 4.4% to $3.43. The company's market cap stands at $27.3 million. </li>
<li>Haoxin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HXHX#NASDAQ">HXHX</a>) stock declined by 4.14% to $1.85. The company's market cap stands at $25.4 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock declined by 3.91% to $1.23. The market value of their outstanding shares is at $26.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIR

CNDT

HKPD

HXHX

NCEW

Nuveen Insured California Premium Fund Ii

SCWO

SOAR

VCIG

WETO

ZONE

12 Industrials Stocks Moving In Tuesday's After-Market Session

Press Releases

Dotdash Meredith Appoints Jim Lawson as President of D/Cipher

Cava Group Set to Join S&P MidCap 400 and Angi to Join S&P SmallCap 600

IAC COMPLETES SPIN-OFF OF ANGI, NOW AN INDEPENDENT COMPANY

New Care.com Research Uncovers a Major Threat to Retention as Employers Underestimate Burnout

IAC TO ANNOUNCE Q1 2025 EARNINGS ON MAY 5th AND HOST EARNINGS CONFERENCE CALL ON MAY 6th

IAC Nominates Tor R. Braham to Board of Directors

IAC Earnings Release Available on Company's Website

IAC to Participate in the 53rd Annual J.P. Morgan Global Technology, Media and Communications Conference

IAC to Participate in the 53rd Annual TD Cowen Technology, Media and Telecom Conference

Care.com Debuts Bold New Look and Enhanced Product Experience, Unlocking the Brand's Next Chapter

ALTR

ANGI

CAVA

SPGI

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Comments

IAC

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO